Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Cheng L, Eng C, Nieman LZ, Kapadia AS, Du XL. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol. 2011;34(6):573–580. doi:10.1097/COC.0b013e3181fe41ed
   PubMedGoogle Scholar
• Thanikachalam K, Khan G. Colorectal cancer and nutrition. Nutrients. 2019;11(1):164. doi:10.3390/nu11010164
   PubMed Web of Science ®Google Scholar
• Afshar S, Sedighi Pashaki A, Najafi R, et al. Cross-resistance of acquired radioresistant colorectal cancer cell line to gefitinib and regorafenib. Iran J Med Sci. 2020;45(1):50–58. doi:10.30476/ijms.2019.44972
   PubMed Web of Science ®Google Scholar
• Tanzadehpanah H, Bahmani A, Hosseinpour Moghadam N, et al. Synthesis, anticancer activity, and β-lactoglobulin binding interactions of multitargeted kinase inhibitor sorafenib tosylate (SORt) using spectroscopic and molecular modelling approaches. Luminescence. 2021;36(1):117–128. doi:10.1002/bio.3929
   PubMedGoogle Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801. doi:10.1056/NEJMoa1802357
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label Phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–1862. doi:10.1016/S0140-6736(17)31601-X
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi:10.1056/NEJMoa1500596
   PubMed Web of Science ®Google Scholar
• Sisik A, Kaya M, Bas G, Basak F, Alimoglu O. CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients. Asian Pac J Cancer Prev. 2013;14(7):4289–4294. doi:10.7314/APJCP.2013.14.7.4289
   PubMedGoogle Scholar
• van der Schouw YT, Verbeek AL, Wobbes T, Segers MF, Thomas CM. Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma. Br J Cancer. 1992;66(1):148–154. doi:10.1038/bjc.1992.233
   PubMed Web of Science ®Google Scholar
• Du F, Liu Y. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. J Clin Lab Anal. 2022;36(1):e24141. doi:10.1002/jcla.24141
   PubMedGoogle Scholar
• Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096–1103. doi:10.1093/annonc/mdz134
   PubMed Web of Science ®Google Scholar
• Zeng Z, Yang B, Liao Z. Biomarkers in immunotherapy-based precision treatments of digestive system tumors. Front Oncol. 2021;11:650481. doi:10.3389/fonc.2021.650481
   PubMedGoogle Scholar
• Cohen R, Hain E, Buhard O, et al. Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status. JAMA Oncol. 2019;5(4):551–555. doi:10.1001/jamaoncol.2018.4942
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Luber B, Tam AJ, et al. Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors. Clin Cancer Res. 2019;25(17):5250–5259. doi:10.1158/1078-0432.CCR-19-0114
   PubMedGoogle Scholar
• Chance O. La valeur des statistiques dans l'etude du cancer du cot de l'utérus [Value of statistics in the study of cancer of the uterine cervix]. C R Soc Fr Gyncol. 1951;21(7):305–311. French.
   PubMedGoogle Scholar
• Ayaz F, Osborne BA. Non-canonical notch signaling in cancer and immunity. Front Oncol. 2014;4:345. doi:10.3389/fonc.2014.00345
   PubMedGoogle Scholar
• Cho OH, Shin HM, Miele L, et al. Notch regulates cytolytic effector function in CD8+ T cells. J Immunol. 2009;182:3380–3389. doi:10.4049/jimmunol.0802598
   PubMed Web of Science ®Google Scholar
• Wang YC, He F, Feng F, et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010;70(12):4840–4849. doi:10.1158/0008-5472.CAN-10-0269
   PubMed Web of Science ®Google Scholar
• Licciulli S, Avila JL, Hanlon L, et al. Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res. 2013;73(19):5974–5984. doi:10.1158/0008-5472.CAN-13-1384
   PubMedGoogle Scholar
• Li X, Wang Y, Li X, Feng G, Hu S, Bai Y. The impact of NOTCH pathway alteration on tumor microenvironment and clinical survival of immune checkpoint inhibitors in NSCLC. Front Immunol. 2021;12:638763. doi:10.3389/fimmu.2021.638763
   PubMedGoogle Scholar
• Tyagi A, Sharma AK, Damodaran C. A review on notch signaling and colorectal cancer. Cells. 2020;9(6):1549. doi:10.3390/cells9061549
   PubMedGoogle Scholar
• Vinson KE, George DC, Fender AW, Bertrand FE, Sigounas G. The notch pathway in colorectal cancer. Int J Cancer. 2016;138(8):1835–1842. doi:10.1002/ijc.29800
   PubMedGoogle Scholar
• Jackstadt R, van Hooff SR, Leach JD, et al. Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis. Cancer Cell. 2019;36(3):319–336.e317. doi:10.1016/j.ccell.2019.08.003
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206. doi:10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. 2015;19(1A):A68–77. doi:10.5114/wo.2014.47136
   Google Scholar
• Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739–1740. doi:10.1093/bioinformatics/btr260
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830.e814. doi:10.1016/j.immuni.2018.03.023
   PubMed Web of Science ®Google Scholar
• Luo P, Lin A, Li K, Wei T, Zhang J. DDR pathway alteration, tumor mutation burden, and cisplatin sensitivity in small cell lung cancer: difference detected by whole exome and targeted gene sequencing. J Thorac Oncol. 2019;14(12):e276–e279. doi:10.1016/j.jtho.2019.08.2509
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61. doi:10.1016/j.cell.2014.12.033
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Racle J, Gfeller D. EPIC: a tool to estimate the proportions of different cell types from bulk gene expression data. Methods Mol Biol. 2020;2120:233–248.
   PubMedGoogle Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Hnzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.
   PubMedGoogle Scholar
• Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(Pt 23):5591–5596. doi:10.1242/jcs.116392
   PubMed Web of Science ®Google Scholar
• Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425–6440. doi:10.1002/jcp.26429
   PubMed Web of Science ®Google Scholar
• Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–737. doi:10.1038/nri3073
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Reiser J, Banerjee A. Effector, memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response. J Immunol Res. 2016;2016:8941260. doi:10.1155/2016/8941260
   PubMed Web of Science ®Google Scholar
• Hodgins JJ, Khan ST, Park MM, Auer RC, Ardolino M. Killers 2.0: NK cell therapies at the forefront of cancer control. J Clin Invest. 2019;129(9):3499–3510. doi:10.1172/JCI129338
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Rengaraju M, D’Andrea A, et al. Producer cells of interleukin 12. Parasitol Today. 1993;9:97. doi:10.1016/0169-4758(93)90215-2
   PubMedGoogle Scholar
• Ma X, Chow JM, Gri G, et al. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med. 1996;183(1):147–157. doi:10.1084/jem.183.1.147
   PubMed Web of Science ®Google Scholar
• Overacre-Delgoffe AE, Chikina M, Dadey RE, et al. Interferon-gamma drives treg fragility to promote anti-tumor immunity. Cell. 2017;169(6):1130–1141.e1111. doi:10.1016/j.cell.2017.05.005
   PubMed Web of Science ®Google Scholar
• Hsu J, Hodgins JJ, Marathe M, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128(10):4654–4668. doi:10.1172/JCI99317
   PubMed Web of Science ®Google Scholar
• Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012;12(4):307–313. doi:10.1038/nrc3246
   PubMed Web of Science ®Google Scholar
• Wang S, He Z, Wang X, Li H, Liu XS. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife. 2019;8. doi:10.7554/eLife.49020
   Web of Science ®Google Scholar
• Wang Z, Zhao J, Wang G, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res. 2018;78(22):6486–6496. doi:10.1158/0008-5472.CAN-18-1814
   PubMed Web of Science ®Google Scholar
• Tran E, Ahmadzadeh M, Lu YC, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387–1390. doi:10.1126/science.aad1253
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199. doi:10.1056/NEJMoa1406498
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, Phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. doi:10.1016/S1470-2045(20)30445-9
   PubMed Web of Science ®Google Scholar
• Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res. 2016;22:807–812. doi:10.1158/1078-0432.CCR-14-3175
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74. doi:10.1126/science.aaa4971
   PubMed Web of Science ®Google Scholar
• Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat Med. 2019;25:389–402. doi:10.1038/s41591-019-0382-x
   PubMed Web of Science ®Google Scholar
• Kelliher MA, Roderick JE. NOTCH signaling in T-cell-mediated anti-tumor immunity and T-cell-based immunotherapies. Front Immunol. 2018;9:1718. doi:10.3389/fimmu.2018.01718
   PubMedGoogle Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic ¦Â-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231–235. doi:10.1038/nature14404
   PubMed Web of Science ®Google Scholar
• Kaler P, Augenlicht L, Klampfer L. Activating mutations in ¦Â-catenin in colon cancer cells alter their interaction with macrophages; the role of snail. PLoS One. 2012;7:e45462. doi:10.1371/journal.pone.0045462
   PubMedGoogle Scholar
• Rodilla V, Villanueva A, Obrador-Hevia A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci USA. 2009;106:6315–6320. doi:10.1073/pnas.0813221106
   PubMed Web of Science ®Google Scholar
• Moradi M, Najafi R, Amini R, et al. Remarkable apoptotic pathway of Hemiscorpius lepturus scorpion venom on CT26 cell line. Cell Biol Toxicol. 2019;35(4):373–385. doi:10.1007/s10565-018-09455-3
   PubMedGoogle Scholar
• Chen J, Du F, Dang Y, et al. Fibroblast growth factor 19-mediated up-regulation of SYR-related high-mobility group box 18 promotes hepatocellular carcinoma metastasis by transactivating fibroblast growth factor receptor 4 and Fms-related tyrosine kinase 4. Hepatology. 2020;71:1712–1731. doi:10.1002/hep.30951
   PubMed Web of Science ®Google Scholar
• Manoochehri H, Jalali A, Tanzadehpanah H, Taherkhani A, Saidijam M. Identification of key gene targets for sensitizing colorectal cancer to chemoradiation: an integrative network analysis on multiple transcriptomics data. J Gastrointest Cancer. 2022;53(3):649–668. doi:10.1007/s12029-021-00690-2
   PubMed Web of Science ®Google Scholar
• Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen En Henegouwen P. The epidermal growth factor. Cell Biol Int. 1995;19:413–430. doi:10.1006/cbir.1995.1086
   PubMed Web of Science ®Google Scholar
• Bahmani A, Tanzadehpanah H, Hosseinpour Moghadam N, Saidijam M. Introducing a pyrazolopyrimidine as a multi-tyrosine kinase inhibitor, using multi-QSAR and docking methods. Mol Divers. 2021;25(2):949–965. doi:10.1007/s11030-020-10080-8
   PubMedGoogle Scholar
• Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med. 2016;38:3–15. doi:10.3892/ijmm.2016.2620
   PubMedGoogle Scholar
• Pulliam SR, Uzhachenko RV, Adunyah SE, Shanker A. Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett. 2016;169:61–72. doi:10.1016/j.imlet.2015.11.007
   PubMedGoogle Scholar
• Wrangle JM, Patterson A, Johnson CB, et al. IL-2 and beyond in cancer immunotherapy. J Interferon Cytokine Res. 2018;38(2):45–68. doi:10.1089/jir.2017.0101
   PubMed Web of Science ®Google Scholar
• Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869. doi:10.3389/fimmu.2018.01869
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016;73(2):377–392. doi:10.1007/s00018-015-2070-4
   PubMed Web of Science ®Google Scholar